The Barrow Brain Tumor Research Center (BBTRC) was founded in 2009 to help spur innovation and progress in the doggedly challenging field of neuro-oncology.
The past 30 years have seen only marginal improvement in the outcomes of brain tumor patients in spite of large amounts of clinical and laboratory research. The BBTRC is adopting miltipronged approach in hopes of accelerating progress. Our goal is to advance 5 distinct lines of research in the lab and then pursue rapid clinical integration where feasible.
Barrow Neurological Institute's status as the national leader in brain tumor patient volume puts us in a unique position to facilitate laboratory research through the clinical trial phase and, it is hoped, bring novel and effective treatments to the market.
The center is currently made up of 2 research labs and will expand to 5 labs over the coming years. Nader Sanai, MD, and Rachael Sirianni, PhD, are the respective principal investigators for the two current laboratories.
Dr. Sanai's lab focuses on the use of new surgical modalities to enhance and maximize the resection of brain tumors while minimizing impact on noncancerous neural structures. Visit the Sanai Lab's home page.
Dr. Sirianni's lab focus is on using polymers and nanotechnology to improve the ability of pharmaceutical oncolytic agents to cross the blood brain barrier and thereby improve efficacy. Visit the Sirianni Lab's home page.
Note: We are actively seeking new principal investigators.
